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C1q deficiency is a rare immunodeficiency, which is strongly associated with the devel-
opment of systemic lupus erythematosus (SLE). A mutation in one of the C1q genes 
can either lead to complete deficiency or to low C1q levels with C1q polypeptide in the 
form of low-molecular weight (LMW) C1q. Patients with C1q deficiency mainly present 
with cutaneous and renal involvement. Although less frequent, neuropsychiatric (NP) 
involvement has also been reported in 20% of the C1q-deficient patients. This involve-
ment appears to be absent in other deficiencies of early components of the complement 
classical pathway (CP) (C1r/C1s, C2, or C4 deficiencies). We describe a new case with 
C1q deficiency with a homozygous G34R mutation in C1qC-producing LMW-C1q pre-
senting with a severe SLE flare with NP involvement. The serum of this patient contained 
very low levels of a LMW variant of C1q polypeptides. Cell lysates contained the three 
chains of C1q, but no intact C1q was detected, consistent with the hypothesis of the 
existence of a LMW-C1q. Furthermore, we provide a literature overview of NP-SLE in 
C1q deficiency and hypothesize about the potential role of C1q in the pathogenesis 
of NP involvement in these patients. The onset of NP-SLE in C1q-deficient individuals 
is more severe when compared with complement competent NP-SLE patients. An 
important number of cases present with seizures and the most frequent findings in neu-
roimaging are changes in basal ganglia and cerebral vasculitis. A defective CP, because 
of non-functional C1q, does not protect against NP involvement in SLE. The absence of 
C1q and, subsequently, some of its biological functions may be associated with more 
severe NP-SLE.
Keywords: complement, C1q deficiency, low molecular weight C1q, neuropsychiatric systemic lupus 
erythematosus, mutation
Abbreviations: ABTS, 2,2′-azino-bis-3-ethyl benzthiazoline-6-sulfonic acid; DXM, dexamethason; ECL, enhanced chemilu-
minescence; ELISA, enzyme-linked immunosorbent assay; HRP, horseradish peroxidase; IFN, interferon; kDa, kilo dalton; 
NGS, next generation sequence; NHS, normal human serum; NP-SLE, neuropsychiatric systemic lupus erythematosus; PBMC, 
peripheral blood mononuclear cell; SDS/PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SLE, systemic lupus 
erythematosus.
FIGURe 1 | Clinical presentation of the C1q-deficient patient. (a) Malar 
rash and discoid lupus leading to mild scarring and atrophy. (B) The 3-T 
magnetic resonance imaging brain (FLAIR image): multifocal diffuse gray 
matter hyperintensities located in the frontotemporal right lobe and 
high-intensity area in multiple regions of the right frontal and parietal lobes. 
(C) Immunofluorescence staining of IgG deposition, C3 deposition, and C1q 
deposition on the kidney. (D) Electron micrograph of the subendothelial 
deposition (arrows) of electron dense material. (e) Electron micrograph of 
mesangial deposition (stars) of electron dense material.
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INtRoDUCtIoN
C1q deficiency is a rare autosomal recessive-inherited defect of 
the complement system caused by mutations occurring in one 
of the three C1q genes (C1qA; C1qB; and C1qC) (1). Up to date, 
three different categories of mutations according to C1q level 
have been described. Apart from non-sense mutations and mis-
sense mutations leading to absence of C1q in serum, a missense 
mutation with detectable C1q levels has been described (2). In 
the last case, some authors have demonstrated a low gradient 
density of C1q compared with healthy controls and is, therefore, 
called low-molecular weight (LMW) C1q (3, 4). Until now, a 
total of 77 C1q deficiency patients in 49 families have been 
described (5–7). An important variability in clinical presenta-
tion and outcome of these patients has been observed, ranging 
from asymptomatic patients to life-threatening encapsulated 
bacterial infections (7–9). C1q deficiency is also strongly related 
to systemic lupus erythematosus (SLE), being so far the most 
penetrant genetic factor predisposing to this disease. From all 
patients described, a total of 85% presented SLE-like symptoms 
while around 50% have been addressed as SLE according to 
the American College of Rheumatology diagnostic criteria 
(1, 3, 4, 7, 8). Cutaneous involvement, oral ulcers, and renal 
involvement are the most consistent manifestations. Although 
nervous system involvement is less frequent, with only 15 
patients described, it can lead to severe neuropsychiatric (NP) 
symptoms.
Several reports, based on mouse models and/or in vitro experi-
ments, describe that C1q plays a role in the brain during different 
developmental stages. C1q can be neuroprotective in the context 
of neurotoxicity induced by beta-amyloid (10, 11), but it is also 
reported to be involved in damage in the context of Alzheimer’s 
disease (12). It remains to be established to what extent C1q is 
involved in cognitive (dys)function in humans and how and in 
which stages of development C1q is protective or damaging to 
brain tissue.
In this report, we describe a new C1q-deficient patient with a 
G34R mutation in the C1qC chain leading to severe NP-SLE and 
review 15 SLE cases with C1q deficiency and NP involvement in 
the literature. Furthermore, we analyze the biochemical structure 
of LMW-C1q in serum and in cell lysates.
patIeNt aND MetHoDs
Clinical presentation of the C1q-Deficient 
patient
A 24-year-old Dutch man was admitted to our hospital with a 
2-day history of progressive weakness and sensory loss of the 
left arm, visual field loss on the left side, and subjective cogni-
tive complaints with regard to concentration and memory. He 
had been diagnosed with a SLE-like illness associated with C1q 
deficiency at the age of 10 months when he presented a butterfly 
rash and antinuclear antibodies (ANAs) positivity. The C1q 
deficiency was caused by a homozygous g.5499G>A mutation at 
the C1qC gene, resulting in a G34R change in the C1q protein. 
Consanguinity was not reported.
At the age of 3 years, he developed polyarthritis, which was 
successfully treated with naproxen. At the age of 7 years, he was 
admitted due to a relapsing polyarthritis and subacute cutaneous 
lupus, fever, aphthous ulcers, sunlight hypersensitivity, malaise, 
and positive antibodies including ANAs, anti-Ro, anti-RNP70, 
and Sm. SLE was diagnosed and hydroxychloroquine 200 mg was 
started. Examination of the past medical history also included 
frequent upper airway and ear infections during the first 3 years of 
his life, pertussis infection at the age of 4 years, relapsing impetigo 
with a Staphylococcus aureus septicemia at the age of 19 years and 
relapsing virus Varicella zoster infection after the age of 20 years.
On the current admission, the patient’s body temperature 
was 37.7°C and blood pressure was 100/60  mmHg. Physical 
examination was remarkable with a butterfly rash (Figure 1A), 
severe sensory loss of the left arm, hyperesthesia of the left hand, 
and homonymous hemianopsia of the left side. Laboratory 
tests revealed increased ESR (63 mm/h; normal <15) and CRP 
(13.7  mg/L; normal <5), a normal hemoglobin, and complete 
blood count. Except for a reduced serum albumin level (31 g/L; 
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normal 34–48), electrolytes, serum cholesterol, renal, and liver 
testing were normal. Analysis of the urine was normal without 
casts or dysmorphic red cells. Protein excretion was 9.87 g/24 h. 
The antibody profile was positive for ANAs, anti-Ro (>240 U/
mL, normal <7), anti-RNP70 (79 U/mL, normal <5), and anti-
Sm antibodies (>120 U/mL, normal <5). Anti-double-stranded 
DNA, anticardiolipin antibodies, Beta-2-GP1 antibodies, lupus 
anticoagulant, anti-phospholipase-A2-receptor (PLA2R), and 
anti-C1q autoantibodies were negative. At this time, analysis of 
complement showed a classical pathway (CP) activity of 0% (nor-
mal >74%), a low alternative pathway (AP) activity (22%, normal 
>39%), a low level of C1q (21  mg/L, normal 102–171  mg/L), 
whereas C3 (1.4  g/L, normal 0.9–2.0  g/L), and C4 (396  mg/L, 
normal 95–415 mg/L) were in the normal range. Blood and urine 
cultures were negative. Findings from the renal biopsy were com-
patible with a class V lupus nephritis, with a “nearly full house” 
immunostaining showing a strong granular staining for IgG and 
a moderate granular staining for C3, both along the glomerular 
basement membrane; a slight granular staining for IgA and IgM, 
and kappa and lambda light chains, sometimes also in mesangial 
areas, but no staining for C1q (Figure 1C). Electron microscopy 
revealed subendothelial, subepithelial, and mesangial deposits 
(Figures 1D,E). A low minimental state examination for the age 
and education of the patient (24, range 0–30) was found. A brain 
computed tomography (CT) scan demonstrated a hyperdensity at 
the right frontal and parietal lobes and a contrast enhanced CT 
showed a bilateral filling defect in the transverse sigmoid sinus. 
A magnetic resonance imaging (MRI) showed multifocal diffuse 
gray matter hyperintensities located in the frontotemporal right 
lobe and high-intensity area on T2 in multiple regions of the right 
frontal and parietal lobes with high-intensities on the diffusion 
weighted imaging study (Figure 1B). A CT-angiography showed 
no signs of cerebral vasculitis. A diagnosis of lupus nephritis type 
V and NP-SLE with both inflammatory and ischemic phenotype 
were established. The patient was treated with daily clopidrogrel 
75 mg and intravenous methylprednisolone 1 g for 3 days plus 
oral prednisone 1  mg/kg/day in a tapering dose, and monthly 
intravenous cyclophosphamide 1 g/m2 for 6 months. Proteinuria 
improved dramatically in the first week and homonymous hemi-
anopsia and cognitive dysfunction resolved after 2 weeks. After 
3 months, the patient still presented a mild sensory loss of the left 
arm. Both the patient and his parents provided informed consent 
for the studies.
samples
Serum and PBMCs, isolated by Ficoll–Paque density gradient cen-
trifugation were collected from the patient and an age-matched 
control. During the admission, a kidney biopsy was performed.
Microscopy
Slides for light microscopy evaluation were stained by hema-
toxylin and eosin, PAS, and silver staining. Immunofluorescent 
stainings on cryostat sections were performed for IgA, IgG, IgM, 
C3, C1q, and kappa and lambda light chains. Part of the renal 
specimen was used for electron microscopy. Pictures were taken 
with a JEM-1011 electron microscope (JEOL USA, Inc.) at vari-
ous magnifications.
Gel Filtration
Gel filtration experiments were carried out using the Äktaprime 
plus system (GE Healthcare, 11001313). Five hundred microlit-
ers of filtered serum sample, either the healthy control serum or 
serum from the C1q-deficient patient, was run through a Hiload 
Superdex Prep grade 200 16/600 column (GE Healthcare), using 
PBS as the running buffer. Fractions of 1  mL were collected 
starting after half an hour for the duration of approximately 50 
fractions. The protein levels in the fractions were analyzed using 
a PierceTM BCA Protein Assay Kit (ThermoFisher Scientific).
C1q eLIsa
The levels of C1q in serum and supernatants were measured using 
an in-house developed ELISA. Maxisorp plates (Nunc) were 
coated with mouse anti-human C1q (Department of Nephrology, 
LUMC) in coating buffer (0.1 M NA2CO3, 0.1 M NaHCO3, pH 
9.6) overnight at 4°C. Plates were washed in PBS/0.05% Tween 
(PBS-T, Sigma). Then the wells were blocked with PBS/1% BSA 
for 1 h at room temperature. After washing, the patient serum 
and control serum were added to the wells in a twofold dilution 
series starting from 1:100 diluted in PBS/1% BSA/0.05% Tween 
(Sigma). After incubation for 1 h at 37°C, the plates were incu-
bated with rabbit anti-human C1q (DAKO) for 1 h at 37°C and 
as detection antibody goat anti-rabbit HRP (DAKO) was used. 
Finally, the substrate was added using ABTS (sigma). The C1q 
levels were measured at an absorbance level of 415 nm.
Western Blot
Using western blot, the composition of C1q was examined by 
detection of the three chains of the C1q protein. Due to the low 
amount of C1q present in the serum of the patient, we applied 
10 times more serum of the patient than the healthy donor. Cell 
lysates and supernatants of stimulated and unstimulated PBMCs 
of the healthy control and the patient were used in the same 
amount in reduced and non-reduced SDS conditions. The west-
ern blot was performed using previously described methods (9).
Reconstitution Complement activity assay
To exclude the possibility that next to C1q deficient, the patients 
sample would also be deficient for C1r or C1s, we performed 
assays to measure activation of the CP of the patient serum by 
reconstitution of purified C1q. Plates coated with human IgG were 
incubated with 1% serum of the patient (diluted in GVB++; 0.1% 
gelatin, 5 mM Veronal, 145 mM NaCl, 0.025% NaN3, 0.15 mM 
CaCl, 0.5 mM MgCl, pH 7.3) with or without addition of puri-
fied C1q (Quidel) in different concentrations. As a read-out, C4 
deposition was measured.
sequencing
Genomic DNA was extracted from blood collected with tubes 
supplemented with EDTA. Sequencing of the complete C1q genes 
(C1qA, C1qB, and C1qC), of both introns and exons was per-
formed as before (9). Deep-sequencing was performed using the 
454 NGS Roche GS FLX Titanium platform. Data were compared 
to internal controls and to Human Genome build 19 as well as 
Human_v37_2 de dbSNP database v132 using the NextGENe 
FIGURe 2 | Genetic analysis of the patient and complement activation assays. (a) Data obtained from deep sequencing show a G34R mutation in the C1qC 
chain. (B) Measurement of the alternative pathway (Wieslab), classical pathway (CP) (Wieslab), C1q, C3, and C4 with nephelometer measurement in the diagnostic 
laboratory. (C) Reconstitution of the CP by adding different concentrations of purified C1q to the patient serum. As a positive control, normal human serum (NHS) 
was used, and as a negative control, heat-inactivated NHS (ΔNHS) was used. C4 deposition was used as detection antibody. (D) C5b9 deposition after adding 
purified C1q to the patient serum and C1q depleted serum. (e) C3c deposition.
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software package for Next Generation Sequence Analysis (NGS) 
from Softgenetics. The effect of the mutation on splicing was 
in silico analyzed using the NetGene2 Server, http://www.cbs.dtu.
dk/services/NetGene2/.
ResULts
Detection of LMW-C1q in serum
With deep sequencing, we identified a homozygous g.5499G>A 
mutation in the C1qC gene, resulting in a change in the C1qC chain 
where glycine was changed into an arginine at position 34 (G34R), 
while both parents show a heterozygous state of the mutation 
(Figure  2A). The routine diagnostics laboratory reported the 
patient to be completely lacking CP activity (Figure 2B). This is 
compatible with a C1q deficiency, but to exclude that next to C1q 
also other factors would be deficient in the patient, we performed 
a reconstitution assay where we add purified C1q to the serum of 
the patient and analyze C4 deposition. To compare the activity, 
we performed the same analysis with C1q-depleted serum. After 
adding purified C1q, we were able to detect C4 deposition at a 
similar range as C1q-depleted serum reconstituted with pC1q 
(Figure 2C). This indicated that the patient was able to produce 
C1r and C1s, C2 and C4, and together with purified C1q was able 
to activate the CP. Furthermore, we were also able to measure 
C5b9 and C3c deposition. This implied that there were no other 
FIGURe 3 | Detection of low-molecular weight-C1q in serum. (a) C1q ELISA by using a dilution range of the serum of the C1q-deficient patient (▲), 
age-matched control (■), and normal human serum (●) as extra control. (B) Western blot analysis of the serum in reduced, non-reduced, and non-reduced/
non-denatured conditions. As positive control, an age-matched control is used. Patient serum was diluted 50× and the healthy control 500×. (C) Protein analysis 
using a BCA protocol and C1q ELISA of different fractions after gel filtration of the serum of a healthy donor. (D) Protein and C1q analysis of the patient.
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complement deficiencies downstream in the complement system 
(Figures 2D,E).
Using ELISA, we could detect a decreased amount of C1q in 
the patient compared to the control samples (Figure  3A). We 
used western blot to examine the molecular structure of C1q in 
the patient serum. In reducing conditions, all the three chains 
of the correct size are detected. However, using non-reducing 
conditions, the dimers of C1q (2 × A–B and 1 × C–C) show an 
abnormal pattern. Using non-reducing/non-denaturing condi-
tions, we were able to detect high-molecular weight C1q in the 
healthy control, but not in the patient, suggesting that the C1q 
of the patient is of a LMW species (Figure 3B). With the usage 
of gel filtration the serum samples of the healthy donor and the 
patient were fractionated on size and with a BCA, the amount 
of protein was analyzed. While the protein profiles of both gel 
filtrations are similar, the location of C1q in the elution profiles is 
clearly different (Figures 3C,D). Please note that since the serum 
of the patient was very low in C1q concentration, we had to use 
different dilutions for the patient and the control in the ELISA to 
detect the presence of C1q in the fractions. These size-exclusion 
chromatography data confirm the LMW nature of C1q in the 
serum of the patient.
Composition of C1q in pBMC of the  
C1q-Deficient patient
To further examine the production of C1q by the cells of the patient 
by Western Blot, we stimulated PBMCs of the patient and the 
control with DXM and IFN-γ to upregulate the C1q production. 
Compared to the serum, we loaded the same amount of lysate 
and supernatant to the lanes. In reducing conditions, we see all 
the three C1q chains in the lysate of the PBMCs (Figure 4A). The 
dimers of C1q can also be detected in the lysates of the PBMCs 
from the patient. However, in non-reducing and non-denaturing 
conditions, the dimers of C1q are detected, while additional 
bands are seen in the PBMCs of the patients, which may indicate 
the presence of intracellular LMW-C1q (Figure 4B).
To examine the composition of secreted C1q, the supernatant 
of the PBMCs was analyzed using western blot. The three chains 
of C1q were detected in the control supernatant as well as in the 
patient supernatant in reducing conditions. Surprisingly, the 
amount of C1q seems comparable between the patient and the 
control (Figure  4C). In non-reducing, non-denaturing condi-
tions, the high molecular size of C1q (460 kDa) is detected only 
in a very low concentration compared to the supernatant of the 
healthy control (Figure 4D).
FIGURe 4 | analysis of stimulated cells from the C1q-deficient patient 
on the presence of C1q, (a) Western blot analysis of cell lysates from 
stimulated pBMCs in reducing conditions, (B) non-reducing and 
non-denaturing conditions. (C) Western blot analysis of the supernatant of 
the PBMCs from the patient and the healthy donor (control) after 72 h of 
culturing in reducing conditions. (D) In non-reducing and non-denatured 
conditions, the cell lysates and supernatant were added in the same amount. 
(e) A schematic representation of intact C1q and low molecular weight 
(LMW)-C1q. In LMW-C1q, positive charges are introduced in the collagen-
like tail due the amino acid exchange Gly-Arg at the N-terminal region 
[modified from Ref. (2)].
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C1q Deficiency and Np-sLe
We performed an extensive electronic literature search from 
1980 to 2016 using online databases (PubMed, Embase, and 
Medline). We found 15 C1q-deficient patients with NP-SLE. 
All these patients presented at least one major central nerv-
ous system (CNS) manifestation. Clinical and neuroimaging 
characteristics of these patients are summarized in Table S1 in 
Supplementary Material. Among all C1q-deficient patients with 
NP-SLE described so far in the literature, seizures was the most 
frequent NP symptom presented (10 patients; 67%) (6, 13–20). 
Furthermore, five patients (33%) presented with a series of severe 
non-specific NP symptoms characterized by encephalopathy and 
difficulties to walk associated with cerebral infarcts and thought 
to be related with a cerebral vasculitis (5, 13, 19–21). Transverse 
myelitis (6, 22) and psychosis (14, 22) were also present in two 
patients (13%). Neuroimaging of the brain showed as more fre-
quent finding affection of basal ganglia (calcification or ischemic 
lesions) in 40% of the cases (16, 17, 19–21, 23) followed by 
cerebral vasculitis (27%) (13, 15, 20, 21) and brain atrophy (20%) 
(6, 17, 24).
DIsCUssIoN
The present study investigated an extremely rare case of C1q defi-
ciency due to non-functional LWM-C1q associated with a severe 
clinical phenotype presenting with membranous lupus nephritis 
and a mixed inflammatory and ischemic NP-SLE. C1q deficiency 
is a very strong susceptibility factor for the development of SLE 
where patients mainly present during childhood with skin or renal 
involvement and less frequently also with NP involvement (7). 
Interestingly, although all the deficiencies of early components 
of the complement CP are known to be a susceptibility factor for 
the development of SLE-like disease, NP involvement appears to 
be absent in C1r/C1s, C2, or C4 deficiencies (24, 25). This makes 
us to speculate about the possible role of C1q in the underlying 
process leading to NP-SLE.
Neuropsychiatric involvement in SLE-related C1q deficiency 
presents with severe major CNS manifestations and its prevalence 
seems to be slightly higher than in complement competent NP-SLE 
patients (20 vs. <5%) (26). Seizures were the most common 
manifestation, presented in 60% of NP-SLE patients. In animal 
models, the production of C1q by neuronal cells was reported 
to lead to opsonization of synapses in the developing postnatal 
CNS, which are next eliminated by microglia (27). Several stud-
ies in murine models have described that C1q plays a role in the 
brain during different developmental stages. A neuroprotective 
role for C1q was reported in the context of beta-amyloid-induced 
neurotoxicity (10, 11), while on the other hand, C1q is reported to 
be involved in damage in the context of Alzheimer’s disease (12). 
The complement system can hence facilitate normal neuronal 
development and protect against damage or contribute to neu-
rodegenerative disease depending on yet to be identified triggers 
and timing. Currently, it has not been formally studied whether 
C1q-deficient patients have cognitive impairments. The neuro-
logical status of the current case completely normalized after the 
successful treatment of the SLE flare with immunosuppression, 
without any residual cognitive impairment. Moreover, studies 
using C1q knockout mice have demonstrated how a defective 
neocortical pruning of excessive excitatory synapses in these 
animals results in spontaneous and evoked epileptiform activity 
and increased intracortical excitatory connectivity (28, 29). This 
may explain the increased prevalence of seizures among these 
patients. Of note, neuroimaging demonstrated that a total of 40% 
of patients with C1q deficiency presenting with NP-SLE showed 
involvement of the basal ganglia and in 27% of these patients 
findings were compatible with cerebral vasculitis. Neuroimaging 
changes in basal ganglia have been rarely reported in SLE patients. 
It has been suggested that these findings may represent vasogenic 
edema and vascular changes occurring due to a vasculitic process 
localized in the basal ganglia probably due to immune-mediated 
underlying pathogenesis or effect of inflammation. Moreover, 
these MRI findings have been described to be reversible after 
starting immunosuppressive therapy (30). SLE-associated vascu-
litis may be associated with the deposition of immune complexes 
(ICs) in the endothelium. The deposition of these ICs may lead 
to endothelial cell activation and inflammatory cell infiltration 
(31). Previous reports have proposed an important role of C1q in 
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the clearance of apoptotic cells and circulating ICs (32, 33). Non-
cleared debris due to absence of C1q may lead to helper T cells 
stimulation and autoantibody production (34, 35). Furthermore, 
in the last years, C1q has been demonstrated to be of importance 
in vascular endothelial permeability and integrity. C1q and 
mannose-binding lectin have been reported in in vitro studies to 
help in the removal of atherogenic lipoproteins, which has been 
proposed as a link between C1q deficiency and cardiovascular 
disease in SLE, as seen in our patient (36, 37).
Globally, more than 60 patients are described with a C1q 
deficiency mostly due to a homozygous mutation. From these 
patients, six have the g.5499G>A mutation resulting in a G34R 
amino acid change and C1q deficiency (4, 14, 16, 17, 20, 38). 
Previous case reports that described the G34R mutation sug-
gested the development of LMW-C1q, which is known as a non-
functional C1q. In this study, we demonstrate a C1q-deficient 
patient with a low level of circulating C1q and an absence of CP 
activity recorded over a long time period. Using sequencing, we 
confirmed a homozygous G34R mutation. As suggested in previ-
ous studies, we also observed that the C1q present in this patient 
is LMW-C1q. Using western blot and gel filtration of the patient 
serum, we detected a different molecular size of C1q in the patient 
serum at low concentrations. When we analyzed the production 
of C1q by PBMCs, we could detect all three C1q chains at a same 
concentration intracellularly, but after analyzing C1q in the 
supernatant in non-reducing and non-denaturing conditions, 
almost no fully folded C1q was detected. This confirms that the 
patient is able to produce all C1q chains but is unable to fold a 
complete functional C1q molecule (Figure 4E). It is conceivable 
that the incorrectly folded C1q polypeptide chains have a strongly 
reduced half-life. Circulating C1q was completely absent after a 
flare of NPSLE. This may suggest that there is consumption of the 
little C1q polypeptide that the patient produces. However, in the 
renal biopsy, no C1q was detected, which could also indicate that it 
is not consumption of LMW C1q but rather a reduced production 
at the time of flare. Although temporary expression of LMW-C1q 
has been reported to occur during SLE flares or even in healthy 
persons, this production is temporary and involves only part of 
the total C1q pool (39, 40). In the current patient, the production 
of LMW-C1q is genetically regulated and permanent and results 
in a completely defective CP.
In conclusion, NP-SLE is a rare but severe complication in C1q 
deficiency patients that must be diagnosed and treated promptly. 
The low level of LMW-C1q observed in the patient did not allow 
any CP activity, making the patient functionally C1q deficient. 
The role of C1q or its absence in the pathogenesis of NP-SLE 
merits further studies.
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